Outcomes after radiation for oligoprogressive disease sites in patients with EGFR-mutant lung cancer treated with osimertinib Journal Article
| Authors: | Chen, M. F.; Jeng, M. Y.; Ma, J.; Agrawal, P.; Dunne, E.; Boe, L. A.; Kris, M. G.; Huang, J.; Veeraraghavan, H.; Gomez, D.; Yu, H. A. |
| Article Title: | Outcomes after radiation for oligoprogressive disease sites in patients with EGFR-mutant lung cancer treated with osimertinib |
| Abstract: | PURPOSE Oligoprogressive disease (OPD) commonly occurs in patients with advanced EGFR mutation-positive non-small cell lung cancer (EGFR+ LC) on systemic therapy. While radiation therapy (XRT) to treat OPD can improve outcomes, the clinical and genomic predictors of benefit from local therapy for oligoprogression on osimertinib are unclear.METHODSWe conducted a single-center retrospective analysis of 81 patients with EGFR+ LC on osimertinib who received XRT for OPD (defined as progression in ≤5 lesions) between January 2014 and December 2022. Progression patterns were identified. Times from local therapy to progression, next therapy, and death were measured.RESULTSThe median duration of osimertinib treatment before XRT was 16.9 months. After XRT, time on osimertinib was extended for a median of 9.7 months, with a median progression-free survival (PFS) and overall survival of 6.9 and 24.4 months, respectively. Post-XRT recurrence was most common in the lung (43%), viscera (35%), and bone (35%), with only 15% of patients experiencing in-field recurrence. Patients receiving XRT to lymph nodes or visceral metastases exhibited shorter PFS compared with other sites. EGFR mutation type, concurrent TP53/RB1 mutations, and mechanisms of resistance did not significantly predict outcomes.CONCLUSIONThe addition of XRT for OPD led to clinically meaningful time on continued osimertinib beyond progression, irrespective of molecular characteristics or resistance mechanisms. © 2025 by American Society of Clinical Oncology. |
| Journal Title: | JCO Precision Oncology |
| Volume: | 9 |
| ISSN: | 2473-4284 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-05-01 |
| Start Page: | e2500047 |
| Language: | English |
| DOI: | 10.1200/po-25-00047 |
| PUBMED: | 40373257 |
| PROVIDER: | scopus |
| PMCID: | PMC12088374 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work